Effect of neurokinin-1 receptor antagonists on serotoninergic, noradrenergic and hippocampal neurons: Comparison with antidepressant drugs

被引：57
作者：
Gobbi, G
Blier, P
机构：
[1] Univ Montreal, Dept Psychiat, Montreal, PQ H3A 1A1, Canada
[2] McGill Univ, Montreal, PQ H3A 1A1, Canada
[3] Univ Ottawa, Royal Ottawa Hosp, Mental Hlth Res Inst, Ottawa, ON K1Z 7K4, Canada
来源：
PEPTIDES | 2005年 / 26卷 / 08期
关键词：
antidepressant; anxiolytic; substance P; antagonist of SP; NK1; receptor; depression; anxiety;
D O I：
10.1016/j.peptides.2005.03.032
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Neurokinin-1 (NK1) receptor antagonists have been reported to possess antidepressant and anxiolytic properties in controlled trials. Since antidepressant and anxiolytic drugs act mainly by enhancing serotonin (5-HT) and norepinephrine (NE) neurotransmission in forebrain areas, the main focus of the present review is to critically examine the electrophysiological effects of NK1 receptor antagonists on serotoninergic and noradrenergic neurons, and then hippocampal neurons. It is concluded that NK1 antagonists increase the firing and burst activity of 5-HT neurons, increase burst activity of NE neurons, and modulate postsynaptic transmission at the hippocampus level. Further research is needed in order to develop more selective ligands for the human NK1 receptor and to gain better knowledge of required brain penetration and optimal pharmacodynamic conditions for their use in patients. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码：1383 / 1393
页数：11
相关论文
共 84 条
  • [1] Effects of microinjections of the neuropeptide substance P in the dorsal periaqueductal gray on the behaviour of rats in the plus-maze test
    Aguiar, MS
    Brandao, ML
    [J]. PHYSIOLOGY & BEHAVIOR, 1996, 60 (04) : 1183 - 1186
  • [2] ALLAM D, 1992, BRIT J PHARMACOL, V107, pP227
  • [3] How does pindolol improve antidepressant action?
    Artigas, F
    Celada, P
    Laruelle, M
    Adell, A
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 2001, 22 (05) : 224 - 228
  • [4] ROLE OF ENDOGENOUS SUBSTANCE-P IN STRESS-INDUCED ACTIVATION OF MESOCORTICAL DOPAMINE NEURONS
    BANNON, MJ
    ELLIOTT, PJ
    ALPERT, JE
    GOEDERT, M
    IVERSEN, SD
    IVERSEN, LL
    [J]. NATURE, 1983, 306 (5945) : 791 - 792
  • [5] Barton C. L., 1999, British Journal of Pharmacology, V126, p284P
  • [6] CSF SUBSTANCE-P IMMUNOREACTIVITY IN AFFECTIVE-DISORDERS
    BERRETTINI, WH
    RUBINOW, DR
    NURNBERGER, JI
    SIMMONSALLING, S
    POST, RM
    GERSHON, ES
    [J]. BIOLOGICAL PSYCHIATRY, 1985, 20 (09) : 965 - 970
  • [7] SEROTONINERGIC BUT NOT NORADRENERGIC NEURONS IN RAT CENTRAL-NERVOUS-SYSTEM ADAPT TO LONG-TERM TREATMENT WITH MONOAMINE-OXIDASE INHIBITORS
    BLIER, P
    DEMONTIGNY, C
    [J]. NEUROSCIENCE, 1985, 16 (04) : 949 - 955
  • [8] The pharmacology of putative early-onset antidepressant strategies
    Blier, P
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2003, 13 (02) : 57 - 66
  • [9] CURRENT ADVANCES AND TRENDS IN THE TREATMENT OF DEPRESSION
    BLIER, P
    DEMONTIGNY, C
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 1994, 15 (07) : 220 - 226
  • [10] SHORT-TERM LITHIUM ADMINISTRATION ENHANCES SEROTONERGIC NEUROTRANSMISSION - ELECTROPHYSIOLOGICAL EVIDENCE IN THE RAT CNS
    BLIER, P
    DEMONTIGNY, C
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1985, 113 (01) : 69 - 77
123456789